backGerman pharmaceutical and chemical company Bayer announced that its subsidiary Monsanto has entered into a proposed settlement that could total up to US$7.25 billion to resolve tens of thousands of lawsuits in the United States involving the herbicide Roundup. The claims—filed by approximately 65,000 plaintiffs—allege that exposure to the product caused non-Hodgkin lymphoma and other cancers following residential or professional use. The agreement, filed in a Missouri state court, provides for the establishment of a nationwide compensation program with capped annual payments over a period of up to 21 years. The arrangement remains subject to judicial approval and a minimum participation threshold among claimants.
According to Bayer, the proposal is also designed to address potential future claims by allowing individuals diagnosed with non-Hodgkin lymphoma who were exposed to Roundup prior to the announcement to seek compensation within a defined timeframe. The settlement does not constitute an admission of liability, and Bayer retains the right to withdraw if participation levels fall short. In parallel, the company has reached confidential agreements with other law firms to resolve specific cases and has already paid approximately US$10 billion under prior settlements concluded through 2020.
The development comes as the United States Supreme Court prepares to consider Bayer’s petition asserting that federal law preempts state-law failure-to-warn claims, on the grounds that the U.S. Environmental Protection Agency does not require a cancer warning label for the product. Bayer has indicated that the Court’s forthcoming decision—expected in April—is critical to achieving long-term resolution of the litigation. Following the announcement, Bayer’s shares rose markedly, reflecting market expectations of reduced legal exposure.
share
